CN1255945A - 利用辅助肽制造肽的方法 - Google Patents
利用辅助肽制造肽的方法 Download PDFInfo
- Publication number
- CN1255945A CN1255945A CN99800113A CN99800113A CN1255945A CN 1255945 A CN1255945 A CN 1255945A CN 99800113 A CN99800113 A CN 99800113A CN 99800113 A CN99800113 A CN 99800113A CN 1255945 A CN1255945 A CN 1255945A
- Authority
- CN
- China
- Prior art keywords
- peptide
- glp
- manufacture method
- record
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
工序 | GLP-1(7-37)/GLP-1(7-36)NH2量(g) | 单个工序收率(%) | 总收率(%) |
培养(相当8L培养液) | 26.87 | 100 | 100 |
OmpT反应 | 22.95 | 85.4 | 85.4 |
SP-sepharose层析 | 20.22 | 98.8 | 76.2 |
酰胺化酶反应 | 20.70 | 100 | 77.0 |
Kex2酶反应 | 18.70 | 90.4 | 69.6 |
MacroPreP HS层析 | 16.78 | 93.7 | 62.4 |
Poros R2层析 | 13.48 | 80.4 | 50.2 |
工序 | 纯度(%) | 单个工序收率(%) | 总收率(%) |
Kex2酶反应 | 15 | - | 100 |
酸沉淀 | - | 68 | 68 |
过滤 | 75 | 88 | 60 |
阳离子交换层析 | 95 | 95 | 57 |
反相层析 | 99 | 72 | 41 |
工序 | 纯度(%) | 单个工序收率(%) | 总收率(%) |
OmpT反应 | 24 | - | 100 |
过滤 | 24 | 90 | 90 |
阳离子交换层析 | 99 | 99 | 89 |
Kex2酶反应 | 96 | 90 | 80 |
反相层析 | 98 | 80 | 64 |
Claims (27)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3227298 | 1998-01-30 | ||
JP32272/1998 | 1998-01-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1255945A true CN1255945A (zh) | 2000-06-07 |
CN1198937C CN1198937C (zh) | 2005-04-27 |
Family
ID=12354362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998001139A Expired - Fee Related CN1198937C (zh) | 1998-01-30 | 1999-01-29 | 利用辅助肽制造肽的方法 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0978565B1 (zh) |
JP (1) | JP4331270B2 (zh) |
KR (1) | KR100627590B1 (zh) |
CN (1) | CN1198937C (zh) |
AT (1) | ATE375393T1 (zh) |
AU (1) | AU765206B2 (zh) |
CA (1) | CA2284847A1 (zh) |
DE (1) | DE69937272T2 (zh) |
DK (1) | DK0978565T3 (zh) |
IL (1) | IL132030A (zh) |
NZ (1) | NZ338004A (zh) |
WO (1) | WO1999038984A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104592381A (zh) * | 2013-10-31 | 2015-05-06 | 江苏万邦生化医药股份有限公司 | 一种利拉鲁肽中间体多肽的制备方法 |
CN105669856A (zh) * | 2016-02-13 | 2016-06-15 | 王大勇 | 一种基因重组长效人促肾上腺皮质激素及其制备方法 |
CN111378027A (zh) * | 2018-12-29 | 2020-07-07 | 万新医药科技(苏州)有限公司 | 一种索玛鲁肽前体的制备方法 |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100916169B1 (ko) | 1999-03-04 | 2009-09-08 | 아스비오파마 가부시키가이샤 | OmpT 프로테아제에 의한 절단 제어 방법 |
WO2001027310A1 (fr) * | 1999-10-15 | 2001-04-19 | Shionogi & Co., Ltd. | Procede de production d'un precurseur d'adrenomeduline |
KR100407792B1 (ko) * | 2000-08-02 | 2003-12-01 | 한국생명공학연구원 | 인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법 |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
ATE469915T1 (de) | 2001-07-27 | 2010-06-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US7138489B2 (en) | 2002-04-11 | 2006-11-21 | Daiichi Asubio Pharma Co., Ltd. | Method for producing a modified peptide |
AU2003239865A1 (en) | 2002-05-24 | 2003-12-12 | Restoragen Inc. | Method for universal enzymatic production of bioactive peptides |
AU2003239863A1 (en) * | 2002-05-24 | 2003-12-12 | Restoragen Inc. | Method for enzymatic production of glp-1 (7-36) amide peptides |
WO2003099854A2 (en) | 2002-05-24 | 2003-12-04 | Nps Allelix Corp. | Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides |
PT2353608T (pt) | 2002-10-11 | 2020-03-11 | Novartis Vaccines And Diagnostics S R L | Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas |
KR20050049525A (ko) * | 2002-10-11 | 2005-05-25 | 가부시키가이샤산와카가쿠켄큐쇼 | Glp-1 유도체 및 그의 경점막 흡수형 제제 |
EP1626981A4 (en) * | 2003-03-04 | 2006-11-22 | Biorexis Pharmaceutical Corp | PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE |
ME01366B (me) | 2003-11-21 | 2013-12-20 | Nps Allelix Corp | POSTUPAK ZA PROIZVODNJU PEPTIDA 2 NALIK NA GLUKAGON l NJIHOVIH ANALOGA |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8114632B2 (en) | 2006-06-21 | 2012-02-14 | Biocon Limited | Method of producing biologically active polypeptide having insulinotropic activity |
WO2008012629A2 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
US20110039776A1 (en) * | 2006-09-06 | 2011-02-17 | Ashutosh Chilkoti | Fusion peptide therapeutic compositions |
EP2307038A4 (en) | 2008-06-27 | 2013-03-27 | Univ Duke | THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES |
WO2014077802A1 (en) * | 2012-11-13 | 2014-05-22 | Ipsen Pharma S.A.S. | Purification method of a glp-1 analogue |
RU2544959C1 (ru) * | 2014-04-04 | 2015-03-20 | Александр Владимирович Бубнов | Способ получения пептидов |
MX2017006866A (es) | 2014-12-01 | 2017-11-15 | Pfenex Inc | Pares de unión para producción de péptidos. |
TWI762706B (zh) | 2017-08-24 | 2022-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1組成物及其用途 |
BR112022013795A2 (pt) | 2020-02-18 | 2022-09-13 | Novo Nordisk As | Composição farmacêutica líquida, e, kit |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3531947B2 (ja) * | 1991-08-19 | 2004-05-31 | 第一サントリーファーマ株式会社 | ペプチドの製造方法 |
JP3995279B2 (ja) * | 1994-09-07 | 2007-10-24 | アスビオファーマ株式会社 | 蛋白の製造方法 |
CA2198966C (en) * | 1996-03-04 | 2011-06-21 | Yuji Suzuki | Method for cleaving chimeric protein using processing enzyme |
-
1999
- 1999-01-29 CN CNB998001139A patent/CN1198937C/zh not_active Expired - Fee Related
- 1999-01-29 JP JP53918299A patent/JP4331270B2/ja not_active Expired - Fee Related
- 1999-01-29 CA CA002284847A patent/CA2284847A1/en not_active Abandoned
- 1999-01-29 KR KR1019997008935A patent/KR100627590B1/ko not_active IP Right Cessation
- 1999-01-29 DE DE69937272T patent/DE69937272T2/de not_active Expired - Lifetime
- 1999-01-29 WO PCT/JP1999/000406 patent/WO1999038984A1/ja active IP Right Grant
- 1999-01-29 IL IL132030A patent/IL132030A/en not_active IP Right Cessation
- 1999-01-29 DK DK99901926T patent/DK0978565T3/da active
- 1999-01-29 AU AU21857/99A patent/AU765206B2/en not_active Ceased
- 1999-01-29 NZ NZ338004A patent/NZ338004A/en not_active IP Right Cessation
- 1999-01-29 EP EP99901926A patent/EP0978565B1/en not_active Expired - Lifetime
- 1999-01-29 AT AT99901926T patent/ATE375393T1/de active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104592381A (zh) * | 2013-10-31 | 2015-05-06 | 江苏万邦生化医药股份有限公司 | 一种利拉鲁肽中间体多肽的制备方法 |
CN105669856A (zh) * | 2016-02-13 | 2016-06-15 | 王大勇 | 一种基因重组长效人促肾上腺皮质激素及其制备方法 |
CN111378027A (zh) * | 2018-12-29 | 2020-07-07 | 万新医药科技(苏州)有限公司 | 一种索玛鲁肽前体的制备方法 |
CN111378027B (zh) * | 2018-12-29 | 2022-04-15 | 万新医药科技(苏州)有限公司 | 一种索玛鲁肽前体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69937272T2 (de) | 2008-07-10 |
ATE375393T1 (de) | 2007-10-15 |
EP0978565B1 (en) | 2007-10-10 |
IL132030A0 (en) | 2001-03-19 |
KR100627590B1 (ko) | 2006-09-25 |
JP4331270B2 (ja) | 2009-09-16 |
EP0978565A4 (en) | 2003-05-02 |
DE69937272D1 (de) | 2007-11-22 |
WO1999038984A1 (fr) | 1999-08-05 |
CN1198937C (zh) | 2005-04-27 |
AU765206B2 (en) | 2003-09-11 |
EP0978565A1 (en) | 2000-02-09 |
AU2185799A (en) | 1999-08-16 |
IL132030A (en) | 2009-06-15 |
DK0978565T3 (da) | 2008-02-04 |
NZ338004A (en) | 2001-08-31 |
KR20010005859A (ko) | 2001-01-15 |
CA2284847A1 (en) | 1999-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1255945A (zh) | 利用辅助肽制造肽的方法 | |
CA1340371C (en) | Methods and products for facile microbial expression of dna sequences | |
CN1030999C (zh) | 胰蛋白酶抑制剂的制备方法 | |
CN1131312C (zh) | 在酵母中表达的n末端延伸蛋白 | |
CN1198844C (zh) | 高***蛋白生产方法 | |
CA2033176C (en) | Growth hormone fusion proteins | |
CN1023900C (zh) | 人初级成纤维细胞生长因子的制备方法 | |
US8298789B2 (en) | Orthogonal process for purification of recombinant human parathyroid hormone (rhPTH) (1-34) | |
CN1483041A (zh) | Glp-1融合蛋白 | |
CN1371424A (zh) | 可活化的重组神经毒素 | |
CN1529757A (zh) | 用于向细菌培养物上清液中分泌目的蛋白质的融合蛋白质 | |
CN1318070A (zh) | 修饰的大肠杆菌内毒素ⅱ信号肽以及表达该肽与异源蛋白质的融合蛋白的微生物 | |
JPH08333395A (ja) | ヒトプロインスリン誘導体およびヒトインスリンの製造方法 | |
CA2094512A1 (en) | Fusion polypeptides | |
CN1231259C (zh) | 生产人胰岛素 | |
CN1291199A (zh) | 含有分子内伴侣样序列的嵌合蛋白及其在胰岛素生产中的应用 | |
KR100989413B1 (ko) | 새로운 융합파트너를 이용한 재조합 단백질의 제조방법 | |
CN1302337A (zh) | 控制OmpT蛋白酶切割的方法 | |
CN1597697A (zh) | 一种人的甲状旁腺素1-34肽相关肽-Pro-Pro-[Arg11]]hPTH(1-34)-Pro-Pro | |
CN85101555A (zh) | 重组脱氧核糖核酸(dna)表达载体和基因表达方法 | |
US20060035316A1 (en) | Plasmids expressing human insulin and the preparation method for human insuling thereby | |
CN1020923C (zh) | 利用dna重组技术生产抑制素的方法 | |
JPH0716432B2 (ja) | 酵母の高発現ベクタープラスミドを用いたペプチドの生産方法 | |
CN86107809A (zh) | 新的重组基因及其应用 | |
JP2005503141A (ja) | アシル化ポリペプチドを作出するための方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUNTORY LTD Free format text: FORMER OWNER: SUNTORY LTD. Effective date: 20030418 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20030418 Address after: Tokyo, Japan Applicant after: Daiichi Suntory Pharma Co., Ltd. Address before: Osaka Applicant before: Suntory Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: SUNTORY LTD |
|
CP03 | Change of name, title or address |
Address after: Tokyo, Japan Patentee after: Daiichi Asubio Pharma Co., Ltd. Address before: Tokyo, Japan Patentee before: Daiichi Suntory Pharma Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: ASTERIX PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME OR ADDRESS: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Tokyo, Japan Patentee after: Asubio Pharma Co., Ltd. Address before: Tokyo, Japan Patentee before: Daiichi Asubio Pharma Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: SANKYO CO. Free format text: FORMER OWNER: ASUBIO PHARMA CO., LTD. Effective date: 20100916 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20100916 Address after: Tokyo, Japan Patentee after: Sankyo Co. Address before: Tokyo, Japan Patentee before: Asubio Pharma Co., Ltd. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050427 Termination date: 20140129 |